• BioInvent announced published first-in-human Phase 1 results for BI-1808 in Clinical Cancer Research, showing preliminary antitumor activity in advanced solid tumors.
• Treatment was well tolerated, with no dose-limiting toxicities, deaths or discontinuations due to drug-related adverse events.
• A gastrointestinal stromal tumor patient maintained a partial response for more than two years; tumor shrinkage also occurred in lung cancer.
• The findings support continued development as monotherapy or combination treatment; Phase 2a cohorts are evaluating recurrent ovarian cancer and cutaneous T-cell lymphoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.